May 3, 2010 - The Memory Improvement with Docosahexaenoic acid (DHA) Study (MIDAS) published online this week in Alzheimer's & Dementia: The Journal of the Alzheimer's Association showed that algal DHA improved memory function in healthy aging adults, providing a benefit roughly equivalent to having the learning and memory skills of someone three years younger.MIDAS is the first large, randomized and placebo-controlled study demonstrating the benefits of algal DHA in maintaining and improving brain health in older adults. The goal of MIDAS was to evaluate the effects of algal DHA on cognitive outcomes in healthy elderly people with a mild memory complaint. The study was funded by Martek Biosciences.
MIDAS found that healthy people with memory complaints who took 900 mg algal DHA capsules for six months had almost double the reduction in errors on a test that measures learning and memory performance versus those who took a placebo, a benefit roughly equivalent to having the learning and memory skills of someone three years younger. The DHA was well-tolerated and subjects taking the DHA also experienced a lower heart rate, providing a significant cardiovascular benefit.
The study population included 485 people 55 and older at 19 U.S. sites who were considered to have age-related cognitive decline. Age-related cognitive decline is defined as decline in cognitive functioning consequent to the aging process that is within normal limits given a person's age. For example, individuals may report problems remembering names or appointments or may experience difficulty solving complex problems.
MIDAS study participants consumed an oral dose of 900 mg per day of algal DHA or a placebo (corn/soy) over the course of six months. The primary endpoint was a cognitive test of memory and learning called the CANTAB Paired Associate Learning (PAL). CANTAB PAL is an assessment of visual memory and new learning, and is a useful tool for assessing patients with age-related memory loss... Martek Biosciences Corporation's Press Release -
April 21st, 2010 - The on-going phase II trial on
March 31st 2010 - 
March 25, 2010 — Currently, Alzheimer's disease cannot be definitively diagnosed until after death, when a brain autopsy is performed on a patient and evidence of beta-amyloid plaque deposits in the brain – which are a characteristic pathology of the disease – can be found. Accurate diagnosis during life can be challenging, particularly in the early stages of Alzheimer's, when symptoms are mild and non-definitive. However,
Avid and Cardinal Health announced that more than 100 clinical centers and more than 700 patients have now participated in a Phase III clinical trial that is testing whether Avid's molecular imaging agent Florbetapir F 18 can detect Alzheimer's disease in living patients. Florbetapir F 18 (also known as 18F AV-45 and Florbetapir) is used with positron emission tomography (PET) technology to detect beta-amyloid plaque deposits in the brain...
Jan 2010 -
April 10, 2010:
April 9, 2010 –
April 1, 2010 -